Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment

Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment

Abstract Objectives With the poorest 5‐year survival of all cancers, improving treatment for pancreatic cancer is one of the biggest challenges in cancer research. We sought to explore the potential of combining both priming and activation of the immune system. To achieve this, we combined a CD40 ag...

Full description

Bibliographic Details
Main Authors: Jonas RM Van Audenaerde, Elly Marcq, Bianca vonScheidt, Ashleigh S Davey, Amanda J Oliver, Jorrit De Waele, Delphine Quatannens, Jinthe Van Loenhout, Patrick Pauwels, Geert Roeyen, Filip Lardon, Clare Y Slaney, Marc Peeters, Michael H Kershaw, Phillip K Darcy, Evelien LJM Smits
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Clinical & Translational Immunology
Subjects:
CD40 agonist
combination immunotherapy
interleukin‐15
natural killer cells
pancreatic cancer
T cells
Online Access:https://doi.org/10.1002/cti2.1165

Internet

https://doi.org/10.1002/cti2.1165

Similar Items